The HSP90 inhibitor, onalespib (AT13387), delays the emergence of resistance to erlotinib in an EGFR-driven xenograft model

被引：0
|
作者：
Courtin, Aurelie [1 ]
Smyth, Tomoko [1 ]
Hearn, Keisha [1 ]
Lyons, John [1 ]
Thompson, Neil [1 ]
Wallis, Nicola G. [1 ]
机构：
[1] Astex Pharmaceut, Cambridge, MA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2688
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2688
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC
    Smyth, Tomoko
    Lewis, Jon
    Hearn, Keisha
    Thompson, Neil
    Lyons, John
    Wallis, Nicola G.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [2] ALTERNATE SYNTHESIS OF HSP90 INHIBITOR AT13387
    Liang, Cuirong
    Gu, Lingling
    Yang, Yang
    Chen, Xin
    [J]. SYNTHETIC COMMUNICATIONS, 2014, 44 (16) : 2416 - 2425
  • [3] Inhibition of Tumour Growth in a Pancreatic Cancer Xenograft Model by AT13387, an HSP90 Inhibitor
    Shaw, E.
    Thomas, A.
    Ghaneh, P.
    Greenhalf, W.
    Davies, M.
    Costello, E.
    Gibbs, F.
    Lyons, J.
    Neoptolemos, J. P.
    Sibson, D. R.
    [J]. PANCREAS, 2011, 40 (08) : 1353 - 1353
  • [4] Combining the HSP90 Inhibitor, AT13387, with Vemurafenib Delays the Emergence of Resistance in a Preclinical Model of BRAFV600E Mutant Melanoma
    Smyth, T.
    Lewis, J.
    Thompson, N.
    Lyons, J.
    Azab, M.
    Wallis, N.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 58 - 58
  • [5] Activity of the HSP90 Inhibitor, AT13387, in ALK-driven Tumor Models
    Wallis, N.
    Smyth, T.
    Munck, J.
    Rodriguez-Lopez, A.
    Lock, V.
    McMenamin, R.
    Thompson, N.
    Lyons, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 90 - 90
  • [6] The HSP90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
    Rodriguez-Lopez, Ana
    Smyth, Tomoko
    McMenamin, Rachel
    Lyons, John
    Thompson, Neil
    Lock, Victoria
    Taverna, Pietro
    Corringham, Robert
    Wallis, Nicola
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [7] Total Synthesis of Resorcinol Amide Hsp90 Inhibitor AT13387
    Patel, Bhavesh H.
    Barrett, Anthony G. M.
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2012, 77 (24): : 11296 - 11301
  • [8] The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
    Kaur, Jatinder
    Bhardwaj, Atul
    Melancon, Bruce J.
    Blagg, Brian S. J.
    [J]. SYNTHETIC COMMUNICATIONS, 2019, 49 (11) : 1436 - 1443
  • [9] The HSP90 inhibitor, AT13387, overcomes resistance to crizotinib and second generation ALK inhibitors
    Courtin, A.
    Smyth, A.
    Hearn, K.
    Martins, V.
    Lewis, J.
    Thompson, N.
    Lyons, J.
    Wallis, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 168 - 168
  • [10] THE HSP90 INHIBITOR, AT13387, DISPLAYS SINGLE AGENT ACTIVITY IN ERLOTINIB-SENSITIVE AND -RESISTANT MODELS OF EGFR-ACTIVATED NSCLC
    Hearn, Keisha
    Smyth, Tomoko
    Lewis, Jon
    Martins, Vanessa
    Thompson, Neil
    Azab, Mohammad
    Lyons, John
    Wallis, Nicola G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S464 - S464
12345